(HealthDay)—Among adults with overweight or obesity, once-weekly subcutaneous semaglutide plus counseling for diet and physical activity results in significantly greater weight loss at 68 weeks than once-daily subcutaneous ...
Jan 21, 2022
0
50
Charles Piller, a contributing correspondent for Science, has published a news article in the journal questioning the medical soundness of referring to prediabetes as a condition that needs treatment. In his article, he points ...
A new chemical process developed by a team of Harvard researchers greatly increases the utility of Positron Emission Tomography (PET) in creating real-time 3-D images of chemical process occurring inside the human body.
Nov 4, 2011
0
0
Major work led by Dr. André Veillette's team at the Institut de recherches cliniques de Montréal (IRCM), in collaboration with a group of researchers, and just published in Nature Immunology, managed to identify a previously ...
Nov 16, 2023
0
493
In a lookback study of prescribing patterns among thousands of American ophthalmologists and optometrists, Johns Hopkins Medicine researchers concluded that eye doctors who receive even small financial incentives from pharmaceutical ...
Aug 15, 2022
0
82
An HIV diagnosis was once a death sentence, but now people who receive treatment survive for decades with the disease. Keeping the virus at bay usually requires taking a pill every day, which aside from being inconvenient ...
May 15, 2019
0
2
COVID-19 vaccine choices are getting more complicated. So don't feel bad if you are confused about the different COVID-19 vaccines and who's eligible for what. In addition to the three original vaccines approved by the Food ...
Oct 8, 2021
0
41
If you've followed the news about Alzheimer's disease research in the past few months, you might find yourself wondering what else could go wrong.
Aug 1, 2022
1
469
A new University of Chicago study has found that the drug masitinib may be effective in treating COVID-19.
Jul 21, 2021
0
236
A promising new natural treatment for Alzheimer's disease is moving toward clinical trials. This will be a major step forward as there is nothing on the market that slows the progression of Alzheimer's.
Mar 11, 2015
1
141
